Enzymatica (ENZY.ST) stock price, revenue, and financials

Enzymatica market cap is kr709.3 m, and annual revenue was kr57.24 m in FY 2021

KR709.3 M

ENZY.ST Mkt cap, 08-Jun-2022

KR4.2 M

Enzymatica Revenue Q1, 2022
Enzymatica Gross profit (Q1, 2022)2.9 M
Enzymatica Net income (Q1, 2022)-18 M
Enzymatica EBITDA (Q1, 2022)-18.1 M
Enzymatica EBIT (Q1, 2022)-18.1 M
Enzymatica Cash, 31-Mar-202220.4 M
Enzymatica EV691.6 M
Get notified regarding key financial metrics and revenue changes at EnzymaticaLearn more
Banner background

Enzymatica Revenue Breakdown

Embed Graph

Enzymatica revenue breakdown by business segment: 100.0% from MEDICAL DEVICES

Enzymatica Income Statement

Annual

SEKFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

52.6m61.3m111.2m57.2m

Cost of goods sold

(10.3m)(10.9m)(29.5m)(19.0m)

Gross profit

43.5m51.5m82.8m40.6m

R&D expense

(20.1m)(26.9m)(22.4m)(24.0m)

Operating expense total

(77.9m)(86.0m)(87.8m)(79.3m)

Depreciation and amortization

(6.2m)(7.1m)(7.0m)(6.6m)

EBITDA

(34.3m)(34.6m)(5.0m)(38.6m)

EBIT

(40.6m)(41.7m)(12.1m)(45.2m)

Interest expense

(2.3m)(1.5m)(803.0k)(889.0k)

Interest income

768.0k189.0k757.0k3.0k

Pre tax profit

(42.1m)(41.9m)(13.1m)(45.7m)

Income tax expense

(429.0k)961.0k(159.0k)307.0k

Net Income

(42.6m)(41.0m)(13.2m)(45.4m)

Quarterly

SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q1, 2022

Revenue

13.3m6.4m19.5m26.8m13.9m28.3m23.1m38.5m4.2m

Cost of goods sold

(3.5m)(2.4m)(5.3m)(5.8m)(5.9m)(7.2m)(12.2m)(17.8m)(1.9m)

Gross profit

10.0m4.2m14.5m21.2m8.3m21.2m11.3m21.7m2.9m

R&D expense

(6.2m)(8.9m)(7.2m)(4.1m)(5.7m)(6.4m)(12.3m)(15.9m)(5.0m)

Operating expense total

(21.9m)(19.8m)(21.6m)(20.9m)(20.2m)(23.4m)(40.0m)(56.4m)(21.0m)

EBITDA

(11.9m)(15.6m)(7.1m)221.0k(11.9m)(2.2m)(28.7m)(34.7m)(18.1m)

EBIT

(11.9m)(15.6m)(7.1m)221.0k(11.9m)(2.2m)(28.7m)(34.7m)(18.1m)

Interest expense

(218.0k)(119.0k)(334.0k)(772.0k)(640.0k)(621.0k)(469.0k)(779.0k)(110.0k)

Interest income

224.0k246.0k(302.0k)896.0k317.0k434.0k373.0k476.0k147.0k

Pre tax profit

(11.9m)(15.5m)(7.8m)345.0k(12.2m)(2.4m)(28.8m)(35.0m)(18.1m)

Income tax expense

(334.0k)(211.0k)19.0k376.0k497.0k467.0k252.0k380.0k61.0k

Net Income

(12.2m)(15.7m)(7.7m)721.0k(11.7m)(1.9m)(28.5m)(34.6m)(18.0m)

Enzymatica Balance Sheet

Annual

SEKFY, 2018FY, 2019FY, 2020FY, 2021

Cash

70.3m29.3m24.0m31.6m

Accounts Receivable

10.4m15.3m32.8m16.3m

Prepaid Expenses

3.1m3.1m4.1m4.0m

Inventories

5.6m7.0m10.5m12.4m

Current Assets

90.0m54.7m71.5m64.8m

PP&E

4.5m6.8m7.4m12.8m

Goodwill

63.2m63.2m63.2m63.2m

Total Assets

185.2m147.7m162.0m157.0m

Accounts Payable

10.2m10.4m13.9m7.6m

Short-term debt

1.7m2.5m12.8m1.5m

Current Liabilities

21.6m24.6m53.3m30.9m

Non-Current Liabilities

3.9m3.9m2.1m1.1m

Total Debt

1.7m2.5m12.8m1.5m

Total Liabilities

25.5m28.5m55.4m32.1m

Common Stock

5.7m5.7m5.7m6.0m

Additional Paid-in Capital

374.2m374.1m376.6m438.8m

Retained Earnings

(220.9m)(261.1m)(273.6m)(319.0m)

Total Equity

159.7m119.2m106.6m125.0m

Quarterly

SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q1, 2022

Cash

53.9m40.8m30.7m33.9m30.9m33.7m64.8m50.0m20.4m

Accounts Receivable

10.1m5.0m16.0m24.4m11.2m12.7m3.1m10.6m5.2m

Inventories

7.0m7.1m5.7m7.6m9.9m9.6m14.0m13.5m13.4m

Current Assets

74.3m56.7m57.0m69.5m56.9m60.3m88.5m80.9m44.6m

PP&E

5.7m5.3m5.3m6.2m6.6m6.6m14.9m14.6m16.2m

Total Assets

168.9m149.5m148.4m160.8m147.7m150.0m182.1m173.2m137.0m

Accounts Payable

7.3m6.5m8.5m11.5m7.8m8.5m8.1m5.1m4.2m

Short-term debt

2.5m2.5m2.4m12.5m12.5m13.0m13.4m12.9m1.9m

Current Liabilities

17.8m14.9m20.8m38.6m35.6m40.7m42.5m37.5m28.4m

Long-term debt

3.8m3.1m2.6m3.2m2.6m1.9m1.6m1.4m834.0k

Non-Current Liabilities

3.8m3.1m2.6m3.2m2.6m1.9m1.6m1.4m834.0k

Total Debt

6.3m5.6m5.1m15.7m15.1m14.9m14.9m14.3m2.7m

Total Liabilities

21.5m18.1m23.5m41.7m38.2m42.7m44.1m38.9m29.3m

Total Equity

147.4m131.5m124.9m119.1m109.4m107.3m138.0m134.3m107.7m

Enzymatica Cash Flow

Annual

SEKFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(40.6m)(41.7m)(12.1m)(45.2m)

Depreciation and Amortization

6.2m7.1m6.2m5.4m

Accounts Receivable

4.6m(4.2m)(19.7m)17.2m

Inventories

(2.9m)(1.4m)(4.0m)(1.8m)

Cash From Operating Activities

(28.8m)(37.6m)(10.7m)(35.9m)

Cash From Investing Activities

(520.0k)(866.0k)(4.8m)(6.1m)

Short-term Borrowings

(815.0k)

Long-term Borrowings

(2.4m)(1.6m)8.3m(11.7m)

Cash From Financing Activities

88.7m(2.5m)10.0m49.5m

Net Change in Cash

59.4m(41.0m)(5.3m)7.6m

Quarterly

SEKQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q1, 2022

Net Income

(11.9m)(27.5m)(34.6m)220.0k(11.7m)(13.9m)(28.7m)(34.7m)(18.1m)

Cash From Operating Activities

(15.6m)(27.8m)(37.5m)(4.5m)(5.8m)(2.4m)(13.1m)(29.3m)(10.2m)

Cash From Investing Activities

(315.0k)(557.0k)(640.0k)(141.0k)(1.1m)(1.6m)(4.5m)(4.9m)(1.2m)

Short-term Borrowings

(433.0k)(864.0k)(1.3m)8.5m(449.0k)(1.3m)

Long-term Borrowings

8.7m65.0k

Cash From Financing Activities

(433.0k)(1.0m)(1.5m)9.3m8.7m8.5m58.4m60.2m65.0k

Net Change in Cash

(16.4m)(29.5m)(39.6m)4.6m1.6m4.4m40.8m26.0m(11.3m)

Enzymatica Ratios

SEKFY, 2018

Revenue/Employee

2.5m

Enzymatica Operating Metrics

Sep, 2016Aug, 2019Oct, 2019Feb, 2020

Enrollment Participants (ColdZyme, Germany)

701

Study Centres (ColdZyme, Germany)

10

Enrollment Participants (ColdZyme, Iceland)

45

Study Centres (ColdZyme, Iceland)

1

Enrollment Participants (ColdZyme, United Kingdom)

88

Study Centres (ColdZyme, United Kingdom)

1

Trademarks

4

Enzymatica Human Capital

Enzymatica's employees are reported to be approximately 53% female and 47% male.
FY, 2019Q3, 2019Q2, 2019Q1, 2019FY, 2018Q3, 2018Q2, 2018Q1, 2018FY, 2017Q3, 2017Q2, 2017Q1, 2017
Male47.1%42.1%40%40%40.9%42.9%42.9%40.9%47.6%47.6%47.6%42.9%
Female52.9%57.9%60%60%59.1%57.1%57.1%59.1%52.4%52.4%52.4%57.1%